BIRC2 and breast cancer: Moreover, BC patients with a high cIAP1-N expression showed a shorter mean OS than patients with a low cIAP1-N expression (45.6 vs. 62.7 months, p<0.01) and a shorter mean recurrence-free survival (RFS, 30.1 months vs. 44.2 months, p<0.01) (28).